Supplementary Methods, Tables 1 - 2 from Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies

作者：Ravi Salgia, Premal Patel, John Bothos, Wei Yu, Steve Eppler, Priti S. Hegde, Shuang Bai, Surinder Kaur, Ihsan Nijem, Daniel V.T. Catenacci, Amy Peterson, Mark J. Ratain, Blasé N. Polite, Janice M. Mehnert, Rebecca A. Moss · 年份：2023 · DOI：10.1158/1078-0432.22451313.v1 · 研究领域：Colorectal Cancer Treatments and Studies、Chronic Lymphocytic Leukemia Research、HER2/EGFR in Cancer Research

<p>PDF file - 88K, Table S1. Treatment-related adverse events across all dosing cohorts in Phase Ia escalation and expansion, and Phase Ib. Table S2. Most commonly reported adverse events regardless of relationship to study drug.</p>